Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
22 July 2025 | Story Nontobeko Nxumalo | Photo Supplied
Mandela Day
The DiMTEC team marked Mandela Day by planting indigenous trees on campus, promoting sustainability and community resilience through nature-based solutions.

The University of the Free State’s (UFS) Centre for Disaster Management Training and Education Centre (DiMTEC) commemorated Nelson Mandela International Day on 18 July by planting trees that help embed nature-based solutions at the heart of disaster risk reduction and climate change adaptation.

“It’s a simple act, yet deeply symbolic – a commitment to sustainability, climate resilience, and future generations,” said Dr Tlou Raphela-Masuku, a Senior Lecturer at DiMTEC. “Nature-based solutions, such as planting indigenous trees, are not just theoretical strategies; they are practical tools to reduce disaster risk, restore ecosystems, and build community resilience.” 

One of the trees planted, the indigenous, resilient Wild Olive (Olea europaea subsp. africana), known locally as Mohlware, embodies the drive to place nature-based solutions at the forefront of disaster risk reduction. “This tree is drought-tolerant and well-adapted to Bloemfontein’s semi-arid climate,” Dr Raphela-Masuku explained. “It stabilises soil, prevents erosion, supports biodiversity, and cools urban spaces. Its thick canopy shelters birds and small mammals, while its deep roots nourish and protect the earth. In a warming world, every Wild Olive planted is a small act of resistance against climate change.” 

 

Collaborative programme

Dr Raphela-Masuku said the tree-planting programme, a collaboration with UFS Protection Services and University Estates, ties directly into the principles the centre teaches in its Master's of Disaster Management module Ecosystem-Based Disaster Risk Reduction (ECO-DRR). 

“From the viewpoint of the African Union’s Science and Technology Advisory Group, it is befitting that as part of the work dedicated to disaster risk reduction initiatives in the African continent, this day is a reminder that we promote community service, resilience and social justice in the ‘Africa we want’. Furthermore, Mandela Day activities align with the Sendai Framework for Disaster Risk Reduction (SFDRR)’s priorities of understanding risks and strengthening disaster governance at all levels,” remarked Prof Alice Ncube, an Associate Professor at DiMTEC.

She added that, “In a city like Bloemfontein, which is not exempt from drought accelerating frequently and temperatures rising yearly, choosing to plant climate-resilient, indigenous species isn’t merely wise, it’s necessary. Trees like the Wild Olive don’t just provide shade and beauty; they help cool urban environments, support biodiversity, and protect our university community from floods and storms. They represent a forward-thinking investment in a sustainable, climate-adapted future. Mandela Day reminds us that service should be continuous, not confined to a single day. A tree planted today will outlive us, offering shade, shelter, and hope to those who come after. As Mandela himself said, ‘The true meaning of life is to plant trees under whose shade you do not expect to sit.’”

 

Commitment to change

Mandela Day also fits in with the UFS’ Vision 130 strategic intent. It is a day that reminds us that everyone has the power to make a difference. In the spirit of Madiba’s legacy, we can commit to fostering social justice, human dignity, and sustainable development through academic excellence and meaningful community engagement. In the face of climate change, biodiversity loss, and environmental degradation, each seed we plant becomes an act of defiance as well as an act of hope.

Prof Samuel Adelabu, Vice-Dean: Postgraduate and Research in the Faculty of Natural and Agricultural Sciences, applauded the team’s efforts. “We are planting trees that represent sustainability, things that can stay for long. I believe we are all practising sustainability in this initiative we are doing today to show that the university, as well as the faculties, are in line with sustainability.” 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept